{"name":"Alder Biopharmaceuticals, Inc.","slug":"alder-biopharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":936000,"revenueGrowth":37,"grossMargin":0,"rdSpend":239108000,"netIncome":-296429000,"cash":426239000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ALD403","genericName":"ALD403","slug":"ald403","indication":"Migraine prevention (episodic and chronic)","status":"phase_3"},{"name":"ALD403 (Eptinezumab)","genericName":"ALD403 (Eptinezumab)","slug":"ald403-eptinezumab","indication":"Episodic migraine prevention","status":"phase_3"}]}],"pipeline":[{"name":"ALD403","genericName":"ALD403","slug":"ald403","phase":"phase_3","mechanism":"ALD403 is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.","indications":["Migraine prevention (episodic and chronic)"],"catalyst":""},{"name":"ALD403 (Eptinezumab)","genericName":"ALD403 (Eptinezumab)","slug":"ald403-eptinezumab","phase":"phase_3","mechanism":"Eptinezumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.","indications":["Episodic migraine prevention","Chronic migraine prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQaE1vUk5uZXBxRS1LWExkOTJ4ZDRCTnBnZGN1SmhBZ2xRQ21ET1M3TEF3QjNWTVJrQXlMRTlfU1JrZjlxTmtJdllBM3NZUFByNTI5VWJGU1drRWpXUXUzTnNLd0JsTGVQam1kVm9mdUlqUUxCcVNZMldHSWpnS2E0eS03clZSUm01Yy1aSlhpd1JLOWN6dXpUbENFanUtNXd6by1OWlFDNjEtNlNsS3JxSG1zdUFnNlBiNmFlekIzUHZxXy1ZQW9OUWhMckN6bThNNmJQR3JrQkZDTjZtcEhySmZjZ3VNZk1nVktBZzFuU2czQjNwaFgweThhb3J2Sy1VN3E3VDFrakxaQmxac09GamNsWjh3LUV6MVNYSA?oc=5","date":"2026-02-24","type":"pipeline","source":"BioSpace","summary":"Slate Medicines Launches with $130 Million Series A Financing to Advance Anti-PACAP Therapies for the Prevention of Migraine and Other Headache Disorders - BioSpace","headline":"Slate Medicines Launches with $130 Million Series A Financing to Advance Anti-PACAP Therapies for the Prevention of Migr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBBeWgyR1RtQnUzT3FsbEFCSlA5U1ZuMFNNSzdmSlRZXzlIaUptWkZXNy1XSmh4a1F6WkdWM2dxS2I0bER5YjZLcU44dDNoeTd5Vm14ZF80V1RUdTJJLUZwTlc5NngxSFE4UUVsV01Lb1JrWUFz?oc=5","date":"2025-01-13","type":"deal","source":"Fierce Pharma","summary":"The top 10 biopharma M&A deals of 2024 - Fierce Pharma","headline":"The top 10 biopharma M&A deals of 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNWW5hTTJSa1pVNWI2MFJPS1pnN1VPbXVYVy14ZVU5V0I0OFFUTFR0eXVqQktVMkhZU2ZzMXYtZ3Y5RW1NR09hRWJLVUlEV21XUW5ub0Y0dDBKV1ZERVg0MVZKamo1UmxvZjNYTDZUTnlmX1MzeDJVSmltU1dIOXJiQ2RsU1ptV1N6QVRZZExldmU3YnI3UXhfZmtfVDktZTZQRlZncEd3WjM2Tm5xTWJyMlA5UnR0cnlLXzlXdjV3ZWctNkxEZ0hXc0loSVQ3dw?oc=5","date":"2022-01-19","type":"pipeline","source":"Business Wire","summary":"Expansion Therapeutics Appoints Gary Bridger, Ph.D., to Its Board of Directors - Business Wire","headline":"Expansion Therapeutics Appoints Gary Bridger, Ph.D., to Its Board of Directors","sentiment":"neutral"},{"date":"2019-10-31","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: ALDER BIOPHARMACEUTICALS, INC.","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOZ0VsUUZWWEQwdFNpNUZvd3NBWm1kZGNPaV9uX09aVnhMMTg1b2tVSnczMHc0N2ZOOHJ4alNib2s2SnYtb3l4MFVZeVpkQ25qUnVRTEstQWF3RlRTTFZaOXBKMWpubnRpME10WUZrUXJTZUc3VGpnRGthOXVZa1FPcjVBaFppcV9kOGZ0d0JPSk5CbVNOWGc?oc=5","date":"2019-09-16","type":"deal","source":"MedCity News","summary":"Lundbeck to acquire Alder BioPharmaceuticals for nearly $2B - MedCity News","headline":"Lundbeck to acquire Alder BioPharmaceuticals for nearly $2B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPd3Y0STNRdFZzc2I3dllZUFRfbFhEVEZHTzJRcFcwaWpxNWpMQ19YcmxSLWoyTHBveUhIbERORThOTmtJbHlvcVB2V09tbTBqODc0Ul9udlZVV1BMUTNDSDA4MFI3Z0syZzV0RFJscHZLTzNTV0MyTC1mRXZFakZiSllIWWJZUC0wc05EU1I5SE95YVZUaU92dg?oc=5","date":"2019-09-16","type":"deal","source":"BioPharma Dive","summary":"Lundbeck buys into migraine, acquiring Alder for $2B - BioPharma Dive","headline":"Lundbeck buys into migraine, acquiring Alder for $2B","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-09-16","type":"deal","source":"GlobeNewswire","summary":"Lundbeck to acquire Alder BioPharmaceuticals – a company - GlobeNewswire","headline":"Lundbeck to acquire Alder BioPharmaceuticals – a company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOSGFFY3Z5N08tUnNwbGJUdWVWZWFJbFVOaElZRHJ5QXJrM2QxTUlGTEFwbGxzSW9CbUlWSzhGYUxCcG13RjlnRnl5U2RsQWcyV2lHVEEwZmtuaEFKQjRzdDRKOGhvYXVYOFlxQTVGbkp3RmtCOHgwcGtaMjZQclEyQjh0TmZfclRya1hQOGM0LW55dllkSHYydUJKS3h1Zm8ydFM4?oc=5","date":"2019-09-16","type":"pipeline","source":"Fierce Biotech","summary":"Lundbeck pens $2B Alder takeover to boost brain disease pipeline - Fierce Biotech","headline":"Lundbeck pens $2B Alder takeover to boost brain disease pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQOHNBb0h5bkpDcWs0aFlPSjl0NzUzek1xZTB6bHJmdWtvT3FHbVZDeU5BNE8xVkNmc2tXT1BqVjZlbDk4bzQ3TUY3ZDdqSVpodDlVM0N1eEo2N2hfS0Q0ZnRDR1QyODYyVUlaN2hiSC1rU25yNFFMdzVkVGJhaXY4QVNsblRFaC1jd0xPUDdfZ2ZsYktoRTJQTVBiRkJYeG85bTBEdFM1TkctVm5ZNm5XcWMzY0xQZ0lNQ1VfSTk1RXhSaHEyLVlUVlh4Sm5IZWxONlEyaGJn?oc=5","date":"2019-04-04","type":"deal","source":"Reuters","summary":"Novartis, Amgen in dispute over migraine drug partnership - Reuters","headline":"Novartis, Amgen in dispute over migraine drug partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQYVRTcmI0X3F3Mzk2NVNjbDFaNnVrMUdQZzRreUg2YTZPU0tnTXg2bEMydjNMbmxieERLSnJadTJtTkRjUzIzX1pRcHRzMUNSdFRNdDhwNC1pUmJRVV9YNEpJZkdUT2o3SXJYcTR4dm9wQWRPU29rQlk0R2t6TUM5TFpySzJZd0ZEcU1tMg?oc=5","date":"2018-03-02","type":"deal","source":"Yahoo Finance","summary":"Teva Pharmaceutical Industries Ltd’s (ADR) (TEVA) GmbH and Alder BioPharmaceuticals Form Global License Agreement - Yahoo Finance","headline":"Teva Pharmaceutical Industries Ltd’s (ADR) (TEVA) GmbH and Alder BioPharmaceuticals Form Global License Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPNFFvWlZSSGNaMzhEeXJIb0htNmNjdmUzanVsV0NRbGl4bzJKUDFkODhYby10YU50OGhwZ0hWSmNiNGlsRkplSi11aElfcG1uLUMtMTdqbXkxaWcwSXVscUl2Vi1wbTItWGhMT0EzOHR3OE42ZVlhWGdfMGM4MVVfZk5Fa1UyOENiUldHZ3pqa1Y3T3ZZLUYydjM5bll2Zw?oc=5","date":"2017-08-10","type":"pipeline","source":"European Medical Journal","summary":"Editor’s Pick : Emerging Treatment Options in Migraine - European Medical Journal","headline":"Editor’s Pick : Emerging Treatment Options in Migraine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQb1YzVnQxbGxueVZ1WXZGOFBiVVJkTjU0bHZEejh1ZEh3MndpYWJBNlJuZ3J2dDE2RDc2QjF0MDA5TlJXWmp2ZGlESTZJYml1NjhMRld3OHg2OTg0ZUxOMWRPcXNNUnI1d2t2a1Rhdl9tTW04bElVdUYtR2s1N2JoSE4xRjNNazEwOUxpQS0zeGR5Z3NaLW95NUdpVWUzUlN2U1RLWtIBpAFBVV95cUxQb1YzVnQxbGxueVZ1WXZGOFBiVVJkTjU0bHZEejh1ZEh3MndpYWJBNlJuZ3J2dDE2RDc2QjF0MDA5TlJXWmp2ZGlESTZJYml1NjhMRld3OHg2OTg0ZUxOMWRPcXNNUnI1d2t2a1Rhdl9tTW04bElVdUYtR2s1N2JoSE4xRjNNazEwOUxpQS0zeGR5Z3NaLW95NUdpVWUzUlN2U1RLWg?oc=5","date":"2017-06-13","type":"pipeline","source":"marketexclusive.com","summary":"Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Files An 8-K Other Events - marketexclusive.com","headline":"Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Files An 8-K Other Events","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9pUU5VVG9FbjhrLVZ0UzliUnRocDhVa3hrT3E5cTF2NXVpSFBRNG5VRmFBRHBJLVp2TkZSZkJyQjhEb2R3YUc0bWlZcmdHTFVuSDl2Rmt3WWFfSXI3MFlyeVl1Z3pVODV0VERwMVJpcEkyYlloclM4YjV6WWZ4RGc?oc=5","date":"2017-06-09","type":"pipeline","source":"thestreet.com","summary":"Biotech Movers: Endo, Inovio, Alder - thestreet.com","headline":"Biotech Movers: Endo, Inovio, Alder","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":936000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":936000,"period":"2017-12-31"},{"value":683000,"period":"2017-06-30"},{"value":113000,"period":"2016-06-30"},{"value":113000,"period":"2016-06-30"},{"value":6436000,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":239108000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-296429000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":426239000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}